



**Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting  
Wednesday, February 21, 2024  
Minutes**

**Approved by the board on April 17, 2024**

**Web link to the meeting video:** <https://youtu.be/OjfiYKppbLo>

**Web link to the meeting materials:** <https://dfr.oregon.gov/pdab/Documents/20240221-PDAB-document-package.pdf>

---

**Call to order and roll call:** Acting Chair Shelley Bailey called the meeting to order at 9:36 am and roll was called.

**Board members present:** Acting Chair Shelley Bailey, Amy Burns, Daniel Hartung, Robert Judge, Christopher Laman, John Murray, and Akil Patterson (arrived at 9:52 am)

**Absent:** None

**Declaration of potential conflict of interest:** John Murray declared a potential conflict of interest as an owner of Murray Drugs and under advisement from the Ethics Commission because of his contracts to provide pharmacy services to public and private insurance companies.

**Welcome new board member:** Ralph Magrish welcomed new board member Christopher Laman. View the meeting video at minute [00:01:50](#).

**Election of Officers:** After the resignation from the chair position by Akil Patterson on Jan. 26, board members needed to elect a new chair. Robert Judge nominated Shelley Bailey, with a second by Amy Burns. View the election of officers in the meeting video at minute [00:03:26](#).

**MOTION to appoint Shelley Bailey as board chair.**

**Board Vote:**

Yes: Amy Burns, Daniel Hartung, Robert Judge, Christopher Laman, John Murray, Chair Shelley Bailey.

No: None

Absent for the vote: Akil Patterson

**Motion passed 6-0**

With the election of Shelley Bailey to chair, board members needed to elect a new vice chair. Amy Burns nominated Robert Judge but he declined due to other obligations. Robert Judge nominated Amy Burns and John Murray provided the second.

**MOTION to appoint Amy Burns as board vice chair.**

**Board Vote:**

Yes: Amy Burns, Daniel Hartung, Robert Judge, Christopher Laman, John Murray, Chair Shelley Bailey.

No: None

Absent for the vote: Akil Patterson

**Motion passed 6-0**

**Approval of minutes:** John Murray made the motion and Robert Judge provided a second to approve the minutes on [Pages 3-5](#) in the agenda packet. View the approval in the meeting video at minute [00:10:07](#).



**MOTION to approve the minutes.**

**Board Vote:**

Yes: Amy Burns, Daniel Hartung, Robert Judge, John Murray, Chair Shelley Bailey.

No: None

Abstain: Christopher Laman

Absent for the vote: Akil Patterson

**Motion passed 5-0**

**Program update by Executive Director Ralph Magrish.** View the executive director's report in the meeting video at minute [00:02:15](#).

**Legislature update by Numi Rehfield-Griffith, senior policy advisory.** View the Legislative update on [Pages 70-77](#) of the agenda packet and view the update in the meeting video at minute [00:14:12](#).

**Board affordability review of Ozempic:** The chair led the board in the affordability review of Ozempic, which included drug-specific public comment on [Pages 23-29](#), board discussion, and potential motion to include Ozempic on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 5-29](#) of the agenda packet. Amy Burns made the motion and Robert Judge provided the second to include Ozempic. View the video of the board discussion at minute [00:36:16](#).

**MOTION to include Ozempic on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.**

**Board Vote:**

Yes: Amy Burns, Robert Judge, John Murray, Christopher Laman, Chair Shelley Bailey.

No: None

Abstain: Akil Patterson

Absent for the vote: Daniel Hartung

**Motion passed 5-0**

**Board affordability review of Trulicity:** The chair led the board in the affordability review of Trulicity, which included drug-specific public comment on [Pages 47-49](#), board discussion, and potential motion to include Trulicity on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 30-49](#) of the agenda packet. Robert Judge made the motion and John Murray provided the second to include Trulicity. View the video of the board discussion at minute [01:00:46](#).

**MOTION to include Trulicity on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon.**

**Board Vote:**

Yes: Amy Burns, Robert Judge, John Murray, Christopher Laman, Chair Shelley Bailey.

No: None

Abstain: Akil Patterson

Absent for the vote: Daniel Hartung



### **Motion passed 5-0**

**Board affordability review of Shingrix:** The chair led the board in the affordability review of Shingrix, which included drug-specific public comment on [Pages 62-69](#), board discussion, and a potential motion to include Shingrix on the list of prescription drugs that may create affordability challenges for health care systems or high out-of-pocket costs for patients in Oregon. The board reviewed the information in the affordability review report on [Pages 50-69](#) of the agenda packet. Board members did not make a motion. View the video of the board discussion at minute [01:24:32](#). View the public comment speakers at minute [01:24:59](#).

**Public comment:** Chair Bailey called on those who signed up to speak to the board. There were two requests to provide oral testimony and two written comments, which are posted to the [PDAB website](#). View the public comments from Susan Schwarz, Global Coalition on Aging, and Dharia McGrew, PhRMA, in the meeting video at minute [01:40:50](#).

**Adjournment:** John Murray made a motion to adjourn and Amy Burns provided a second. Chair Bailey adjourned the meeting at 11:17 am and announced the next board meeting on March 20, 2024 at 9:30 am. View adjournment at minute [01:46:27](#).